{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:40:18Z","timestamp":1791186018568,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1007\/s00198-002-1349-0","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T01:03:45Z","timestamp":1478480625000},"page":"56-65","source":"Crossref","is-referenced-by-count":36,"title":["Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies"],"prefix":"10.1007","volume":"14","author":[{"given":"J. Y.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,3,12]]},"reference":[{"key":"1349_CR1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jbmr.5650110203","volume":"11","author":"Parfitt","year":"1996","unstructured":"Parfitt AM, Mundy GR, Roodman GD, et al. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996;11:1509.","journal-title":"J Bone Miner Res"},{"key":"1349_CR2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","volume":"338","author":"Eastell","year":"1998","unstructured":"Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736\u201346.","journal-title":"N Engl J Med"},{"key":"1349_CR3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"Neer","year":"2001","unstructured":"Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434\u201341.","journal-title":"N Engl J Med"},{"key":"1349_CR4","unstructured":"Arlot ME, Roux JP, Boivin G, et al. Effects of strontium salt (S 12911) in both tibial metaphysis and epiphysis in normal growing rats [abstract]. J Bone Miner Res. 1995;10(Suppl 1):abstr M415."},{"key":"1349_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/8756-3282(96)00080-4","volume":"18","author":"Canalis","year":"1996","unstructured":"Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent salt S 12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18:517\u201323.","journal-title":"Bone"},{"key":"1349_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-2999(02)02040-X","volume":"450","author":"Baron","year":"2002","unstructured":"Baron R, Tsouderos Y. In vitro effects of S12911\u20132 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002;450:11\u20137.","journal-title":"Eur J Pharmacol"},{"key":"1349_CR7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jbmr.5650080512","volume":"8","author":"Marie","year":"1993","unstructured":"Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607\u201315.","journal-title":"J Bone Miner Res"},{"key":"1349_CR8","unstructured":"Amman P, Robin B, Bonjour JP, et al. Long-term exposure to strontium ranelate dose-dependently increases bone strength in intact female rats [abstract]. Bone 2001;5(Suppl):S220."},{"key":"1349_CR9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1053\/meta.2002.33360","volume":"51","author":"Delannoy","year":"2002","unstructured":"Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002;51:906\u201311.","journal-title":"Metabolism"},{"key":"1349_CR10","doi-asserted-by":"crossref","unstructured":"Marie PJ. Effects of strontium on bone formation and bone cells. In: Neve J, editor. Therapeutic use of trace elements. New York: Plenum Press, 1996:277\u201382.","DOI":"10.1007\/978-1-4899-0167-5_48"},{"key":"1349_CR11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/jbmr.5650110915","volume":"11","author":"Boivin","year":"1996","unstructured":"Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res 1996;11:1302\u201311.","journal-title":"J Bone Miner Res"},{"key":"1349_CR12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1385\/JCD:2:1:37","volume":"2","author":"Slosman","year":"1999","unstructured":"Slosman DO, Provvedini DM, Meunier PJ, et al. The use of different dual X-ray absorptiometry brand in a multicenter clinical trial. J Clin Densitom 1999;2:37\u201344.","journal-title":"J Clin Densitom"},{"key":"1349_CR13","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(89)92927-9","volume":"II","author":"Reginster","year":"1989","unstructured":"Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;II:1469\u201371.","journal-title":"Lancet"},{"key":"1349_CR14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","volume":"338","author":"Hosking","year":"1998","unstructured":"Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485\u201392.","journal-title":"N Engl J Med"},{"key":"1349_CR15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","volume":"131","author":"Ravn","year":"1999","unstructured":"Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131: 935\u201342.","journal-title":"Ann Intern Med"},{"key":"1349_CR16","first-page":"2784","volume":"82","author":"Meunier","year":"1997","unstructured":"Meunier PJ, Confavreux E, Tupinon I, et al. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997;82: 2784\u201391.","journal-title":"J Clin Endocrinol Metab"},{"key":"1349_CR17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF03343728","volume":"23","author":"Adami","year":"2000","unstructured":"Adami S, Bruni V, Bianchini D, et al. Prevention of early postmenopausal bone loss with cyclical etidronate. J Endocrinol Invest 2000;23: 310\u20136.","journal-title":"J Endocrinol Invest"},{"key":"1349_CR18","doi-asserted-by":"crossref","unstructured":"Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized two-year, double-masked, dose-ranging, placebo, controlled PREVOS trial. Osteoporos Int 2002;13: 925\u201331.","DOI":"10.1007\/s001980200129"},{"key":"1349_CR19","first-page":"2060","volume":"87","author":"Meunier","year":"2002","unstructured":"Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: the STRATOS 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87: 2060\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"1349_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-117-1-1","volume":"117","author":"Lufkin","year":"1992","unstructured":"Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:19.","journal-title":"Ann Intern Med"},{"key":"1349_CR21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","volume":"322","author":"Storm","year":"1990","unstructured":"Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265\u201371.","journal-title":"N Engl J Med"},{"key":"1349_CR22","unstructured":"CPMP: Committee for Proprietary Medical Products. Note for guidance on postmenopausal osteoporosis in women. London, January 2001. CPMP\/EWP\/559\/98."},{"key":"1349_CR23","unstructured":"Food and Drug Administration. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. USA: Division of Metabolism and Endocrine Drug Products, FDA: 1994."},{"key":"1349_CR24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637\u201345.","journal-title":"JAMA"},{"key":"1349_CR25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study. N Engl J Med 1995;333:1437\u201343.","journal-title":"N Engl J Med"},{"key":"1349_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s001980170147","volume":"12","author":"Cranney","year":"2001","unstructured":"Cranney A, Guyatt G, Krolocki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001;12:140\u201351.","journal-title":"Osteoporos Int"},{"key":"1349_CR27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83\u201391.","journal-title":"Osteoporos Int"},{"key":"1349_CR28","unstructured":"Boivin G, Schenker E, Tupinon-Mathieu I, et al. Uptake and distribution of strontium in human bone, evolution of the degree of mineralisation after strontium ranelate administration. J Bone Miner Res 1999;14(Suppl 1):284."},{"key":"1349_CR29","unstructured":"Meunier PJ, Roux C, Ortolani S, et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int 2002;13(Suppl 1):O45."}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-002-1349-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-002-1349-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-002-1349-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-002-1349-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:21:56Z","timestamp":1718882516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-002-1349-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":29,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s00198-002-1349-0","relation":{},"ISSN":["0937-941X"],"issn-type":[{"value":"0937-941X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}